Chinese Journal of Dermatology ›› 2020, Vol. 53 ›› Issue (1): 66-71.doi: 10.35541/cjd.20180838
• Reviews • Previous Articles Next Articles
Chen Binglin, Xue Meijuan, Yang Ji, Li Ming
Received:
2018-10-23
Revised:
2019-04-17
Online:
2020-01-15
Published:
2019-12-31
Contact:
Yang Ji
E-mail:yang.ji@zs-hospital.sh.cn
Supported by:
Chen Binglin, Xue Meijuan, Yang Ji, Li Ming. Diagnosis and treatment of systemic sclerosis-associated interstitial lung disease: current status and advances[J]. Chinese Journal of Dermatology, 2020, 53(1): 66-71.doi:10.35541/cjd.20180838
[1] | Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?[J]. Arthritis Rheumatol, 2014,66(8):1967⁃1978. doi: 10.1002/art.38702. |
[2] | Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma[J]. Arthritis Rheum, 2000,43(11):2437⁃2444. doi: 10.1002/1529⁃0131(200011)43:113.0.CO;2⁃U. |
[3] | 杨骥, 崔祥祥, 李明. 系统性硬化病63例内脏累及与自身抗体检测[J]. 中华皮肤科杂志, 2018,51(1):31⁃33. doi: 10.3760/cma.j.issn.0412⁃4030.2018.01.008. |
[4] | 崔祥祥, 杨骥, 屠文震, 等. 系统性硬化病患者的皮肤表现及其临床意义[J]. 中华皮肤科杂志, 2018,51(1):14⁃19. doi: 10.3760/cma.j.issn.0412⁃4030.2018.01.004. |
[5] | Volkmann ER, Tashkin DP. Treatment of systemic sclerosis⁃related interstitial lung disease: a review of existing and emerging therapies[J]. Ann Am Thorac Soc, 2016,13(11):2045⁃2056. doi: 10.1513/AnnalsATS.201606⁃426FR. |
[6] | Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma[J]. Rheum Dis Clin North Am, 2015,41(2):237⁃248. doi: 10.1016/j.rdc.2014.12.005. |
[7] | Tiev KP, Hua⁃Huy T, Kettaneh A, et al. Serum CC chemokine ligand⁃18 predicts lung disease worsening in systemic sclerosis[J]. Eur Respir J, 2011,38(6):1355⁃1360. doi: 10.1183/0903 1936.00004711. |
[8] | De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis[J]. J Rheumatol, 2013,40(4):435⁃446. doi: 10.3899/jrheum.120725. |
[9] | Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment[J]. Rheumatol Int, 2017,37(6):853⁃863. doi: 10.1007/s00296⁃016⁃3636⁃7. |
[10] | Silver KC, Silver RM. Management of systemic⁃sclerosis⁃associated interstitial lung disease[J]. Rheum Dis Clin North Am, 2015,41(3):439⁃457. doi: 10.1016/j.rdc.2015.04.006. |
[11] | Suliman YA, Dobrota R, Huscher D, et al. Brief report: pulmonary function tests: high rate of false⁃negative results in the early detection and screening of scleroderma⁃related interstitial lung disease[J]. Arthritis Rheumatol, 2015,67(12):3256⁃3261. doi: 10.1002/art.39405. |
[12] | Silver KC, Silver RM. Management of systemic⁃sclerosis⁃associated interstitial lung disease[J]. Rheum Dis Clin North Am, 2015,41(3):439⁃457. doi: 10.1016/j.rdc.2015.04.006. |
[13] | Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence⁃based recommendations for point⁃of⁃care lung ultrasound[J]. Intensive Care Med, 2012,38(4):577⁃591. doi: 10.1007/s00134⁃012⁃2513⁃4. |
[14] | Wang Y, Gargani L, Barskova T, et al. Usefulness of lung ultrasound B⁃lines in connective tissue disease⁃associated interstitial lung disease: a literature review[J]. Arthritis Res Ther, 2017,19(1):206. doi: 10.1186/s13075⁃017⁃1409⁃7. |
[15] | Ferro F, Delle SA. The use of ultrasound for assessing interstitial lung involvement in connective tissue diseases[J]. Clin Exp Rheumatol, 2018,36 Suppl 114(5):165⁃170. |
[16] | Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis⁃associated interstitial lung disease are not predictive of disease progression[J]. Arthritis Rheum, 2007,56(6):2005⁃2012. doi: 10.1002/art.22696. |
[17] | Chowaniec M, Skoczyńska M, Sokolik R, et al. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management[J]. Reumatologia, 2018,56(4):249⁃254. doi: 10. 5114/reum.2018.77977. |
[18] | Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system[J]. Am J Respir Crit Care Med, 2008,177(11):1248⁃1254. doi: 10.1164/rccm.200706⁃877OC. |
[19] | Iudici M. What should clinicians know about the use of glucocorticoids in systemic sclerosis?[J]. Mod Rheumatol, 2017,27(6):919⁃923. doi: 10.1080/14397595.2016.1270796. |
[20] | Steen VD, Medsger TA. Case⁃control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis[J]. Arthritis Rheum, 1998,41(9):1613⁃1619. doi: 10.1002/1529⁃0131(199809)41:93.0.CO;2⁃O. |
[21] | Kowal⁃Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017,76(8):1327⁃1339. doi: 10.1136/annrheumdis⁃2016⁃209909. |
[22] | Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1⁃year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease[J]. Am J Respir Crit Care Med, 2007,176(10):1026⁃1034. doi: 10.1164/rccm.200702⁃326OC. |
[23] | Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double⁃blind, placebo⁃controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma[J]. Arthritis Rheum, 2006,54(12):3962⁃3970. doi: 10.1002/art.22204. |
[24] | Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open⁃label study[J]. J Rheumatol, 2008,35(6):1064⁃1072. |
[25] | Iudici M, Cuomo G, Vettori S, et al. Low⁃dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc⁃ILD): efficacy of maintenance immunosuppression in responders and non⁃responders[J]. Semin Arthritis Rheum, 2015,44(4):437⁃444. doi: 10.1016/j.semarthrit.2014.09.003. |
[26] | Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. a systematic review[J/OL]. PLoS One, 2015,10(5):e0124205. [2018⁃07⁃01]. https://doi.org/10.1371/journal.pone.0124205. doi: 10.1371/journal.pone.0124205. |
[27] | Ueda T, Sakagami T, Kikuchi T, et al. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis[J]. Respir Investig, 2018,56(1):14⁃20. doi: 10.1016/j.resinv.2017.11.004. |
[28] | Tzouvelekis A, Galanopoulos N, Bouros E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis⁃associated interstitial lung disease: a meta⁃analysis[J]. Pulm Med, 2012,2012:143637. doi: 10.1155/2012/143637. |
[29] | Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma⁃related interstitial lung disease (SLS II): a randomised controlled, double⁃blind, parallel group trial[J]. Lancet Respir Med, 2016,4(9):708⁃719. doi: 10.1016/S2213⁃2600(16)30152⁃7. |
[30] | Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis⁃⁃a retrospective analysis[J]. Rheumatology (Oxford), 2007,46(3):442⁃445. doi: 10.1093/rheumatology/kel244. |
[31] | Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma⁃related interstitial lung disease (SLS II): a randomised controlled, double⁃blind, parallel group trial[J]. Lancet Respir Med, 2016,4(9):708⁃719. doi: 10.1016/S2213⁃2600(16)30152⁃7. |
[32] | Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin⁃induced murine pulmonary fibrosis[J]. Eur J Pharmacol, 2008,590(1⁃3):400⁃408. doi: 10.1016/j.ejphar.2008.06.046. |
[33] | King TE, Bradford WZ, Castro⁃Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014,370(22):2083⁃2092. doi: 10.1056/NEJMoa1402582. |
[34] | Khanna D, Albera C, Fischer A, et al. SAT0433 safety and tolerability of pirfenidone in patients with systemic sclerosis⁃associated interstitial lung disease⁃the Lotuss study. Ann Rheum Dis, 2015, 74:816. |
[35] | Khanna D, Saggar R, Mayes MD, et al. A one⁃year, phase I/IIa, open⁃label pilot trial of imatinib mesylate in the treatment of systemic sclerosis⁃associated active interstitial lung disease[J]. Arthritis Rheum, 2011,63(11):3540⁃3546. doi: 10.1002/art.30548. |
[36] | Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group[J]. Ann Rheum Dis, 2015,74(6):1188⁃1194. doi: 10.1136/annrheumdis⁃2013⁃204522. |
[37] | Karimi⁃Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis⁃⁃FDA review of pirfenidone and nintedanib[J]. N Engl J Med, 2015,372(13):1189⁃1191.doi:10.1056/NEJMp1500526. |
[38] | Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo⁃controlled clinical trial of nintedanib in patients with systemic sclerosis⁃associated interstitial lung disease (SENSCIS™)[J]. Clin Exp Rheumatol, 2017,35 Suppl 106(4):75⁃81. |
[39] | Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo⁃controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis[J]. Arthritis Rheum, 2010,62(7):2101⁃2108. doi: 10.1002/art.27466. |
[40] | King TE, Brown KK, Raghu G, et al. BUILD⁃3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2011,184(1):92⁃99. doi: 10.1164/rccm.201011⁃1874OC. |
[41] | 刘磊, 薛愉, 邹和建. 系统性硬化症靶向治疗进展[J]. 上海医药, 2017,38(z1):67⁃69. doi: 10.3969/j.issn.1006⁃1533.2017.z1. 016. |
[42] | Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease[J]. Ther Adv Respir Dis, 2017,11(8):327⁃340. doi: 10.1177/1753465817713680. |
[43] | Cutolo M, Sulli A, Pizzorni C, et al. Systemic sclerosis: markers and targeted treatments[J]. Acta Reumatol Port, 2016,41(1):18⁃25. |
[44] | Volkmann ER, Tashkin DP. Treatment of systemic sclerosis⁃related interstitial lung disease: a review of existing and emerging therapies[J]. Ann Am Thorac Soc, 2016,13(11):2045⁃2056. doi: 10.1513/AnnalsATS.201606⁃426FR. |
[45] | Eyraud A, Scouppe L, Barnetche T, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature[J]. Br J Dermatol, 2018,178(3):650⁃658. doi: 10.1111/bjd.15993. |
[46] | Sullivan KM, Goldmuntz EA, Keyes⁃Elstein L, et al. Myeloablative autologous stem⁃cell transplantation for severe scleroderma[J]. N Engl J Med, 2018,378(1):35⁃47. |
[47] | Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study[J]. Arthritis Rheumatol, 2015,67(5):1314⁃1322. doi: 10.1002/art.39021. |
[1] | Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888. |
[2] | Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786. |
[3] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625. |
[4] | Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544. |
[5] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
[6] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023)” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |
[7] | Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China (2023) [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488. |
[8] | Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566. |
[9] | Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2023, 56(5): 471-475. |
[10] | Wang Min, He Pingxiu, Cheng Lifang, Hong Kechun, Ai Yong. A case of meningothelial hamartoma of the scalp [J]. Chinese Journal of Dermatology, 2023, 56(5): 449-450. |
[11] | Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414. |
[12] | Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis (2023) [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388. |
[13] | Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269. |
[14] | Wang Shiqi, Wang Aiping, Li Hang, Li Ruoyu. Comparison of dermoscopic features of toenail psoriasis and fingernail psoriasis [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220544-e20220544. |
[15] | Wang Li, Wang Qianqiu, Zhang Ruili. Research progress in latent syphilis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220283-e20220283. |
|